TyrNovo is developing NT219, a small molecule originally developed by Dr. Hadas Reuveni and Prof. Alexander Levitzki at the Hebrew University, and exclusively licensed from Yissum, the Hebrew University Research Development Company. TyrNovo demonstrated the potential of NT219 to overcome resistance to multiple anti-cancer drugs, by using the Patient-Derived Xenograft (PDX) models, in collaboration with Prof. Izhak Haviv from the Bar-Ilan University and Prof. M. Stemmer from Clalit HMO.
No less than 50 Israeli start ups currently develop Cannabis-related technologies, and the Hebrew University's new startup CannabiTech is here to make a change.
Nutraceutical pain reliever makes use of marijuana’s CBD compound, doesn’t make you high.
Sales based on Israeli startup Lyotropic Delivery Systems (LDS) Biotech‘s nanotechnology have started in the US. The commercial launch of its cannabis-derived compound, which aims to relieve inflammation and pain, was announced earlier this month by LDS and US based company Ananda Scientific at a marijuana business conference held in Las Vegas.
The potential of the students' project was first identified at a science fair by Tamir Huberman a business development specialist for the university's for-profit company, Yissum, which aims to turn the best ideas originated at the university into businesses. He says "as a rule of thumb" about $500,000 is needed to help fund the wider trials and get this technology into development . It is hoped it will be available within two years.
Still controversial in the US, Israel is leading the way to develop the next generation of Medical Cannabis.
Just last month, Yissum (the technology transfer company of the Hebrew University) announced that Agrinnovation, its investment fund focused on agricultural innovation, has entered into an investment agreement with MC company Cannabi-Tech. In a company announcement, Agrinnovation General Manager Dr. Ido Schechter said that, “As the MC industry expands worldwide, there will be a significant rise in regulatory oversight, increased quality assurance and quality control testing, while growing market demand will need to be fulfilled by mass production.”
Atox Bio, a clinical stage company developing novel immunemodulators for critically ill patients with severe infections, today announced the independent Data Monitoring Committee (DMC) completed its pre-planned safety review of the first 50 patients enrolled in the company's ACCUTE trial and recommended that the study, evaluating novel candidate AB103 for the treatment of Necrotizing Soft Tissue Infections ("Flesh Eating Bacteria"), continue without modification.
Drug now being tested causes HIV-infected cells to self-destruct without harming the rest of the body
Agrinnovation puts money into Cannabi-Tech, developer of an analysis device for medical marijuana flowers
Granalix BioTechnologies today announced the commercial launch of GranaGard™ a food supplement based on pomegranate oil that was shown to prevent neurodegeneration diseases in mouse models.
Granalix BioTechnologies focuses on developing science-based novel formulations of natural antioxidants that can be used for the prevention and treatment of neurodegenerative conditions. The Company was established in 2014 by Prof. Ruth Gabizon from the Department of Neurology at Hadassah Medical Center, Jerusalem, Israel and Prof.Shlomo Magdassi at the Casali Center for Applied Chemistry, the Institute of Chemistry and the Center for Nanoscience and Nanotechnology at the Hebrew University of Jerusalem, as a spinoff of Yissum Research Development Company of the Hebrew University of Jerusalem, the technology-transfer company of the Hebrew University, and Hadasit, the Technology Transfer Company of Hadassah Medical Organization.
Agrinnovation, the agri-tech investment fund of Hebrew University of Jerusalem technology commercialization company Yissum, has announced an investment in a medical cannabis venture. Cannabi-Tech is based on research by cofounder and chief scientific officer Prof. Oded Shoseyov, whose technologies are also the basis for other startups, including Collplant and Fulcrum.
BriefCam was added to the toolbox of Hartford's Real-Time Crime and Data Intelligence Center about three months ago, after members of the center's staff first saw it in action at ESPN, which sometimes aids police with enhancing video files.
Inventions using sound and touch soon to be commercialized from Israeli professor’s lab will give unprecedented abilities to people with visual limitations.
Belgium's Ion Beam Applications S.A. has also signed an OEM agreement with Jerusalem-based HIL Applied Medical
As the effectiveness of social networking in tech transfer has become increasingly apparent, more and more TTO leaders have engaged with a number of social networks to enhance their marketing efforts. But while many have enjoyed some level of success from their endeavors, it is unlikely that few, if any, can match the nearly 40,000 LinkedIn connections and impressive business achievements achieved by Tamir Huberman, MSc, BSc, vice president of business development for computer science and IT director at Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.
CNN's Oren Liebermann visits a company that will help Rio monitor its bank of surveillance cameras and help authorities keep track of whats happening at street level.
Yissum Research Development Company Ltd., the technology transfer arm of the Hebrew University of Jerusalem, today announced that RenewSense was selected to enter Brainnovation, Israel's Brain Technologies accelerator. RenewSenses, based on research from the lab of Professor Amir Amedi, from the Department of Medical Neurobiology at the Hebrew University of Jerusalem and the Edmond & Lily Safra Center for Brain Science, develops devices that can aid the blind and visually-disabled to navigate using other senses like sound and touch.
Therapix Biosciences, (OTCQB: THXBY) (TASE: THXBY.TA), a pharma company specializing in the development and commercialization of cannabinoid-based drugs, announced today that it entered into a binding memorandum of understandings with Yissum, the technology transfer company of the Hebrew University of Jerusalem, to receive an exclusive, worldwide license to use a patent-protected formulation for nasal administration of cannabinoid substances. The technology, developed by Prof. Elka Touitou from the Institute of Drug Research at the Hebrew University of Jerusalem, facilitates administration and effective absorption of the active ingredient THC nasally.
Yissum announced that it has signed a non-exclusive worldwide licensing agreement and a consulting agreement with Lightricks for the development and commercialization of an imaging technology that improves digital image processing. The technology, invented by Prof. Raanan Fattal from the School of Computer Science and Engineering at theHebrew University of Jerusalem, is called "Edge Avoiding Wavelets" and it enables better and faster detail enhancement and preserves edges when sharpening digital images.
Yissum, the technology transfer company of the Hebrew University of Jerusalem, has over 9,300 patents and 110 spin-offs to its name. The 52-year old company–the third oldest in the world of its kind–works closely with researchers at the university and connects them to commercial partners such as Intel and Google. It also creates an average of 10 new companies per annum, with some like Mobileye valued at over $9 billion today.
According to Yissum’s vice-president of marketing Dana Gavish-Fridman, Yissum-commercialized products generate over $2 billion in annual sales, with the company receiving a healthy three to five percent in royalties. Other sources of income include equity and investments by industry players.